Advaxis, Inc. (ADXS) Sets New 52-Week Low at $2.97
Advaxis, Inc. (NASDAQ:ADXS) reached a new 52-week low during mid-day trading on Tuesday . The stock traded as low as $2.97 and last traded at $3.22, with a volume of 466900 shares trading hands. The stock had previously closed at $3.39.
Several equities research analysts recently issued reports on ADXS shares. BidaskClub lowered Advaxis from a “hold” rating to a “sell” rating in a research note on Monday, July 31st. ValuEngine lowered Advaxis from a “sell” rating to a “strong sell” rating in a research note on Tuesday, August 8th. HC Wainwright reissued a “buy” rating and set a $23.00 price objective on shares of Advaxis in a research note on Friday, September 15th. Finally, Cantor Fitzgerald reissued a “buy” rating and set a $19.00 price objective on shares of Advaxis in a research note on Monday, September 25th.
Advaxis (NASDAQ:ADXS) last released its quarterly earnings results on Monday, September 11th. The biotechnology company reported ($0.80) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.53) by ($0.27). Advaxis had a negative net margin of 655.66% and a negative return on equity of 93.54%. The firm had revenue of $3.05 million for the quarter, compared to analysts’ expectations of $3.43 million. equities research analysts anticipate that Advaxis, Inc. will post -2.21 EPS for the current year.
In other news, CFO Sara Bonstein sold 12,734 shares of Advaxis stock in a transaction dated Thursday, November 2nd. The stock was sold at an average price of $3.19, for a total value of $40,621.46. Following the transaction, the chief financial officer now owns 244,504 shares in the company, valued at $779,967.76. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, major shareholder Adage Capital Partners Gp, L.L sold 600,000 shares of Advaxis stock in a transaction dated Wednesday, October 11th. The stock was sold at an average price of $4.30, for a total value of $2,580,000.00. The disclosure for this sale can be found here. Insiders have sold 1,872,291 shares of company stock worth $8,163,810 in the last 90 days. Company insiders own 7.21% of the company’s stock.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its holdings in shares of Advaxis by 9.2% in the first quarter. Vanguard Group Inc. now owns 1,663,010 shares of the biotechnology company’s stock worth $13,587,000 after buying an additional 139,710 shares during the period. Geode Capital Management LLC increased its holdings in shares of Advaxis by 4.8% in the first quarter. Geode Capital Management LLC now owns 279,812 shares of the biotechnology company’s stock worth $2,286,000 after buying an additional 12,736 shares during the period. Swiss National Bank increased its holdings in shares of Advaxis by 17.5% in the first quarter. Swiss National Bank now owns 55,800 shares of the biotechnology company’s stock worth $456,000 after buying an additional 8,300 shares during the period. OxFORD Asset Management LLP purchased a new position in shares of Advaxis in the second quarter worth about $498,000. Finally, Tudor Investment Corp ET AL purchased a new position in shares of Advaxis in the first quarter worth about $283,000. Hedge funds and other institutional investors own 47.88% of the company’s stock.
WARNING: “Advaxis, Inc. (ADXS) Sets New 52-Week Low at $2.97” was originally published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this report on another website, it was illegally copied and republished in violation of U.S. and international copyright law. The original version of this report can be accessed at https://theolympiareport.com/2017/11/14/advaxis-inc-adxs-sets-new-52-week-low-at-2-97.html.
Advaxis, Inc is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins.
Receive News & Ratings for Advaxis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.